HRAS and cancer: Certain genes, such as the RAS family of proteins (KRAS, NRAS, and HRAS, the most frequently mutated oncogenes in cancer [13]), the MYC proto-oncogene (MYC, a commonly amplified gene [14,15]), and tumor protein 53 (TP53, the most frequently altered tumor suppressor gene in human cancer [16]), present significant challenges to pharmacological targeting and have been categorized as “undruggable” [12].